UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934
(Amendment No. )

 

Filed by the Registrant ☒

 

Filed by a Party other than the Registrant ☐

 

Check the appropriate box:

 

Preliminary Proxy Statement
   
Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2))
   
Definitive Proxy Statement
   
Definitive Additional Materials
   
Soliciting Material under § 240.14a-12

 

AIM ImmunoTech Inc.

(Name of Registrant as Specified in its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):

 

No fee required
   
Fee paid previously with preliminary materials
   
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

 

 

 

On September 26, 2022, AIM ImmunoTech Inc. (the “Company”) began mailing the below mailer to stockholders of the Company along with copies of the Amendment No. 1 to the Company’s Definitive Proxy Statement and accompanying revised WHITE proxy card, which were filed with the U.S. Securities and Exchange Commission on September 21, 2022.

 

 

 

 

AIM ImmunoTech (AMEX:AIM)
Graphique Historique de l'Action
De Oct 2022 à Nov 2022 Plus de graphiques de la Bourse AIM ImmunoTech
AIM ImmunoTech (AMEX:AIM)
Graphique Historique de l'Action
De Nov 2021 à Nov 2022 Plus de graphiques de la Bourse AIM ImmunoTech